Seeking Alpha

Heavily-shorted Questcor (QCOR +6.1%) surges after receiving more positive sell-side commentary...

Heavily-shorted Questcor (QCOR +6.1%) surges after receiving more positive sell-side commentary (previous), this time from Jefferies, which is upgrading shares to Buy. Analyst Biren Amin believes investors are pricing Questcor as if almost no insurers will provide coverage for its Acthar gel for treating nephrotic syndrome or MS, something he considers unrealistic.
Comments (1)
  • 85% of prescriptions were reimbursed.
    10 Oct 2012, 12:40 PM Reply Like
DJIA (DIA) S&P 500 (SPY)